Autoimmunity in Retinitis Pigmentosa
Not Applicable
- Conditions
- Retinitis Pigmentosa
- Registration Number
- NCT00433277
- Lead Sponsor
- Semmelweis University
- Brief Summary
Using local immune suppression, the trial seeks evidence for the hypothesis that autoimmunity plays a role in the pathomechanism of retinitis pigmentosa.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- Clinical diagnosis of retinitis pigmentosa
Exclusion Criteria
- Cataract
- Extremely low ERG wave amplitude (less than 8% of normal)
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms link autoimmunity to retinitis pigmentosa progression in NCT00433277?
How does local immune suppression compare to standard-of-care treatments for retinitis pigmentosa?
Which biomarkers are associated with immune response modulation in retinitis pigmentosa patients?
What are the potential adverse events of local immune suppression in retinal diseases?
Are there combination therapies involving immune modulators for retinitis pigmentosa treatment?
Trial Locations
- Locations (1)
Semmelweis University, Dept. of Ophthalmology
🇭🇺Budapest, Hungary
Semmelweis University, Dept. of Ophthalmology🇭🇺Budapest, Hungary